Institutional members access full text with Ovid®

Share this article on:

Current and novel bronchodilators in respiratory disease

Spina, Domenico

Current Opinion in Pulmonary Medicine: January 2014 - Volume 20 - Issue 1 - p 73–86
doi: 10.1097/MCP.0000000000000012
ASTHMA: Edited by Nicola A. Hanania and Zuzana Diamant

Purpose of review β2-Agonists and muscarinic antagonists are widely used to treat asthma and chronic obstructive pulmonary disease (COPD), and a number of novel drug targets are being investigated for potential clinical utility. This review will summarize current developments in the field.

Recent findings The clinical effectiveness of a number of once a day inhaled β2-agonists and muscarinic antagonists is a major advance providing sustained bronchodilation in asthma and COPD. The identification of novel targets (e.g. bitter taste receptor TASR2), the demonstration of clinical effectiveness of others [e.g. phosphodiesterase (PDE)3/4] and exploring the potential of inverse agonists/biased agonists are evidence of continuing interest in the development of novel bronchodilators.

Summary Novel long-acting β2-agonists (e.g. indacaterol, vilanterol, olodaterol and carmoterol) and muscarinic antagonists (e.g. tiotropium, aclidinium, glycopyrronium and umeclidinium bromide) document sustained bronchodilation and their combination provides additional benefits over monotherapy. Not surprisingly, inhaled long-acting β2-agonist and long-acting muscarinic antagonists remain the drugs of choice for maintenance bronchodilation. However, there is a continued interest in developing novel bronchodilators illustrated by the clinical effectiveness of long acting mixed PDE3/4 inhibitors, vasointestinal peptide adenylyl cyclase agonists and inverse agonists/biased agonists for the β2-adrenoceptor, and the identification of intracellular (e.g. Rho kinase, exchange proteins activated by cyclic AMP) and cell surface (e.g. TAS2R, natriuretic peptide receptor) targets.

Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Biomedical Science, King's College London, London, UK

Correspondence to Domenico Spina, PhD, Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, School of Biomedical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK. Tel: +44 207 848 4341; fax: +44 207 848 4500; e-mail: domenico.spina@kcl.ac.uk

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins